ReviewJournal of thoracic disease2020
Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparison of dosimetric parameters and delivery accuracy between conformal radiotherapy-intensity modulated radiotherapy-combined and intensity-modulated radiotherapy planning for central lung cancer patients receiving stereotactic body radiotherapy.Quantitative imaging in medicine and surgery · 2026Article
- An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer.Clinical lung cancer · 2026Article
- Impact of respiratory motion on dose to the airways in central and ultra-central lung stereotactic ablative body radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Article
- The Evolving Role of Local Radiotherapy in the Management of Oligometastatic Non-Small Cell Lung Cancer.Cancer management and research · 2026Review
- Feasibility of Very High Cumulative Equivalent Dose in 2 Gy Fraction in Locally Advanced Central/Ultracentral Nonsmall Cell Lung Cancer Treated With Conventional Chemoradiation Therapy and a Stereotactic Boost.Advances in radiation oncology · 2026Article
- Factors Associated With Local Control and Toxicity of Hypofractionated Radiotherapy for Early and Late-Stage Ultracentral Lung Tumors.Clinical lung cancer · 2025Article
- Application of respiratory motion management technology for patients with lung cancer treated with stereotactic body radiotherapy (Review).Oncology letters · 2025Review
- Assessment of toxicity in patients with ultra-central thoracic tumours treated with stereotactic body radiotherapy with a dose of 50 Gy in 5 fractions.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Quantitative evaluation of accumulated and planned dose deviations in patients undergoing gated and non-gated lung stereotactic body radiation therapy patients: a retrospective analysis.Translational lung cancer research · 2024Article
- The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.Journal of clinical medicine · 2024Review
- Multi-institutional study using sbrt to treat mediastinal and hilar lymphadenopathy.Clinical & experimental metastasis · 2024Article
- The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).Oncology reports · 2024Review
- Article
- Article
- Key changes in the future clinical application of ultra-high dose rate radiotherapy.Frontiers in oncology · 2023Article
- Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?World journal of clinical oncology · 2022Review
- Lattice or Oxygen-Guided Radiotherapy: What If They Converge? Possible Future Directions in the Era of Immunotherapy.Cancers · 2021Review
- Late Central Airway Toxicity after High-Dose Radiotherapy: Clinical Outcomes and a Proposed Bronchoscopic Classification.Cancers · 2021Article
- Narrative Review: Cardiotoxicities and Cardiac-Sparing Techniques in Radiotherapy.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in imaging and radiotherapy (RT) techniques have allowed for remarkably precise delivery of high radiation dose per treatment fraction to intrathoracic targets. As a non-invasive therapeutic modality (compared to surgery), stereotactic body radiotherapy (SBRT) is an attractive option for patients with early-stage non-small cell lung cancers and oligometastases, especially for older patients with significant comorbidities and pre-existing pulmonary dysfunction. However, the outcomes and side effect profile of SBRT are highly dependent on tumor location, especially if the tumor is located centrally (within 2 cm of the proximal bronchial tree (PBT)] or ultracentrally (touching or within 1 cm of the mediastinum, esophagus, and PBT). In this focused review, we will examine the contemporary practice and principles of using hypofractionated RT or SBRT for central and ultracentral thoracic tumors. We will identify future directions on how this practice may be incorporated into the increasingly complicated modern paradigm of lung cancer treatments which now include immunotherapy along with proton beam radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.